Is Immune Checkpoint Inhibition Part of Standard Therapy for Stage III Non-Small Cell Lung Cancer?

Cancer - United States
doi 10.1002/cncr.31557
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Immune Checkpoint Modulation for Non-Small Cell Lung Cancer

Clinical Cancer Research
Cancer ResearchOncology
2015English

Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer

Cancer
Cancer ResearchOncology
2017English

Neoadjuvant Chemoradiotherapy for Stage III Non-Small Cell Lung Cancer

Frontiers in Oncology
Cancer ResearchOncology
2017English

Immune-Checkpoint Inhibitor Treatment of Non-Small Cell Lung Cancer Patients

Jurnal Respirasi
2020English

Advances in Immune Therapy for Non Small Cell Lung Cancer

Medical Diagnosis
2016English

Patterns of Care for Stage III Non-Small Cell Lung Cancer in Australia

Asia-Pacific Journal of Clinical Oncology
MedicineOncology
2019English

The Predictive Value of Tumor Mutation Burden for Immune Checkpoint Inhibitors Therapy in Non-Small Cell Lung Cancer Is Affected by Patients’ Age

Biomarker Research
BiochemistryMolecular MedicineClinical Biochemistry
2020English

Prognostic Value of Neutrophil-To-Lymphocyte Ratio Following Chemoradiation Therapy for Stage III Non–small Cell Lung Cancer

International Journal of Radiation Oncology Biology Physics
OncologyRadiologyCancer ResearchRadiationNuclear MedicineImaging
2017English

Is Smoking History the Truly Best Biomarker for Immune Checkpoint Inhibitor Treatment in Advanced Non-Small Cell Lung Cancer?

ESMO Open
Cancer ResearchOncology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy